Taurochenodeoxycholic acid (12-Deoxycholyltaurine) is a taurine-conjugated bile acid [1]. Taurochenodeoxycholic acid activates receptors such as FXR (farnesoid X receptor) and TGR5, regulating liver, intestinal and systemic metabolism [2-3]. Taurochenodeoxycholic acid is mainly studied in glucose metabolism, lipid metabolism, and inflammatory response [4].
In NR8383 cells, Taurochenodeoxycholic acid (1-100μM; 48h) treatment enhanced the apoptosis rate of cells [5]. In fibroblast-like synoviocytes, Taurochenodeoxycholic acid (50-400μg/mL; 48h) induces apoptosis of cells [6]. In SGC-7901 cells, aurochenodeoxycholic acid (0-100μg/mL; 12-48h) inhibits the proliferation and invasion of gastric cancer and induces its apoptosis [7].
In experimental autoimmune encephalomyelitis (EAE) mice model, Taurochenodeoxycholic acid (25mg/kg, 50mg/kg; po; 23d) administration could improve the nerve damage of EAE mice [8]. In Staphylococcus aureus-infected mice, Taurochenodeoxycholic acid (0.1μg/g; ip; 1h) reduced secretion levels of inflammatory mediators and lung injury in Staphylococcus aureus-infected mice via TLR2 [9].
References:
[1]. Uchida A, Yamada T, Hayakawa T, et al. Taurochenodeoxycholic acid ameliorates and ursodeoxycholic acid exacerbates small intestinal inflammation[J]. American Journal of Physiology-Gastrointestinal and Liver Physiology, 1997, 272(5): G1249-G1257.
[2]. Song G, Weng F, Zou B, et al. Potential therapeutic action of tauroursodeoxycholic acid against cholestatic liver injury via hepatic Fxr/Nrf2 and CHOP-DR5-caspase-8 pathway[J]. Clinical Science, 2023, 137(7): 561-577.
[3]. Qi Y, Shi L, Duan G, et al. Taurochenodeoxycholic acid increases cAMP content via specially interacting with bile acid receptor TGR5[J]. Molecules, 2021, 26(23): 7066.
[4]. Bao L, Hao D, Wang X, et al. Transcriptome investigation of anti‐inflammation and immuno‐regulation mechanism of taurochenodeoxycholic acid[J]. BMC Pharmacology and Toxicology, 2021, 22(1): 23.
[5]. Wang X, Zhang Z, He X, et al. Taurochenodeoxycholic acid induces NR8383 cells apoptosis via PKC/JNK-dependent pathway[J]. European Journal of Pharmacology, 2016, 786: 109-115.
[6]. Li L, Liu C, Liu M, et al. Taurochenodeoxycholic acid induces apoptosis of fibroblast-like synoviocytes[J]. European journal of pharmacology, 2013, 706(1-3): 36-40.
[7]. Zhang D, Zhu Y, Su Y, et al. Taurochenodeoxycholic acid inhibits the proliferation and invasion of gastric cancer and induces its apoptosis[J]. Journal of Food Biochemistry, 2022, 46(3): e13866.
[8]. Xu N, Bai Y, Han X, et al. Taurochenodeoxycholic acid reduces astrocytic neuroinflammation and alleviates experimental autoimmune encephalomyelitis in mice[J]. Immunobiology, 2023, 228(3): 152388.
[9]. Gong Z, Mao W, Ren P, et al. Taurochenodeoxycholic acid ameliorates the Staphylococcus aureus infection-induced acute lung injury through toll-like receptor 2 in mice[J]. International Immunopharmacology, 2024, 142: 113228.
Taurochenodeoxycholic acid (12-Deoxycholyltaurine)是一种牛磺酸结合胆汁酸 [1]。Taurochenodeoxycholic acid激活FXR（法尼醇X受体）和TGR5等受体，调节肝脏、肠道和全身代谢 [2-3]。Taurochenodeoxycholic acid主要在糖代谢、脂质代谢和炎症反应方面进行研究 [4]。
在NR8383细胞中，Taurochenodeoxycholic acid（1-100μM；48h）处理可增加细胞凋亡率 [5]。在成纤维细胞样滑膜细胞中，Taurochenodeoxycholic acid（50-400μg/mL；48h）可诱导细胞凋亡 [6]。在SGC-7901细胞中，Taurochenodeoxycholic acid（0-100μg/mL；12-48h）可抑制胃癌的增殖和侵袭，并诱导其凋亡 [7]。
在实验性自身免疫性脑脊髓炎（EAE）小鼠模型中，Taurochenodeoxycholic acid（25mg/kg、50mg/kg；po；23d）给药可改善EAE小鼠的神经损伤 [8]。在金黄色葡萄球菌感染小鼠中，Taurochenodeoxycholic acid（0.1μg/g；ip；1h）通过TLR2降低金黄色葡萄球菌感染小鼠炎症介质的分泌水平和肺损伤 [9]。